PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for July 22, 2005 Subscribe to this News Feed    
 

American Medical Association Endorses Drug Experiments on Children

The American Medical Association has issued a report advocating the training of investigators to study the effects of psychotropic drugs on children, adolescents, and young adults. The AMAs statements within this report indicate that it views both the FDA Black Box Suicide Warning on these drugs, and the issue of full informed consent as a restriction. This comes despite their conclusions that The use of antidepressants is associated with a doubling in the number of reports indicative of suicidal thinking and behavior in children and adolescents with Major Depressive Disorder and other psychiatric disorders."

(PRWEB) July 22, 2005 -- The American Medical Association has issued a report advocating the training of investigators to study the effects of psychotropic drugs on children, adolescents, and young adults. According to the AMA, SSRIs should remain available for use in children and adolescents, including for unlabeled uses." SSRIs were a popular class of antidepressants that have been the subject of widespread controversy, banned in Great Britain in 2003 for use in children and adolescents due to their propensity to induce suicidal thoughts and ideations, and more recently given black box labels in 2004 by the Food and Drug Administration.

The AMAs statements indicate that it views both the FDA Black Box Suicide Warning on these drugs, and the issue of full informed consent as a restriction. This comes despite their conclusions that The use of antidepressants is associated with a doubling in the number of reports indicative of suicidal thinking and behavior in children and adolescents with Major Depressive Disorder and other psychiatric disorders."

Ablechild contacted the FDA to obtain a comment regarding the AMAs report which promotes the experimental use of drugs that are known to increase suicidal tendencies. According to FDA Spokesperson, Susan Cruzan, The FDA has reviewed all the scientific data and incorporated two advisory boards recommendations on the link to suicide ideation, resulting in a Black Box Warning recommending close oversight for all that use antidepressants to look for increased suicide ideation. The FDA worked with the manufacturers on the Black Box warning mandated on all antidepressants."

According to Bill Hall, Health & Human Services Spokesman, "HHS regulates all human subjects research carried out by those institutions and organizations that have signed assurances with the HHS Office for Human Research Protections (OHRP)." Unfortunately, OHRP is not funded to track all unlabeled usage of psychotropic drugs as promoted by the AMA in their recent report.

Based on the statements of both organizations we have concluded that there is insufficient oversight of experimental use of psychotropic drugs on children.

OHRP must protect all citizens from becoming unknowing victims of experimental research.

The promotion of unlabeled SSRI use on children by the AMA, when the dangers and risks associated with the usage is well documented, is unethical and irresponsible. It undermines the FDAs role, its recommendations, and jeopardizes overall public health.

The AMA needs to be reminded that disclosing drug risks to the public and promoting full disclosure should not be seen as a barrier, but as requisite to public health and safety.

Ablechild is an IRS approved, nonprofit, tax-exempt, Section 501(c) (3) charitable organization, and donations are tax deductible under the provisions of the IRS Code. Ablechild and the Ablechild logo is a Trademark of Ablechild, Inc. For more information, go to http://www.ablechild.org

Contact
Sheila Matthews
National Vice President
203-966-8419

###

Other Releases by this Member
OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Patricia Weathers
ABLECHILD.ORG
845-677-4118
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.